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e aim of this study was to develop a dual-modality PET/MR imaging probe by radiolabeling iron oxide magnetic nanoparticles
(IONPs), surface functionalizedwithwater soluble stabilizer 2,3-dicarboxypropane-1,1-diphosphonic acid (DPD), with the positron
emitter Gallium-68. Magnetite nanoparticles (Fe3O4 MNPs) were synthesized via coprecipitation method and were stabilized
with DPD. e Fe3O4-DPD MNPs were characterized based on their structure, morphology, size, surface charge, and magnetic
properties. In vitro cytotoxicity studies showed reduced toxicity in normal cells, compared to cancer cells. Fe3O4-DPDMNPs were
successfully labeled with Gallium-68 at high radiochemical purity (>91%) and their stability in human serum and in PBS was
demonstrated, along with their further characterization on size and magnetic properties. e ex vivo biodistribution studies in
normal Swiss mice showed high uptake in the liver followed by spleen. e acquired PET images were in accordance with the ex
vivo biodistribution results. Our ndings indicate that 68Ga-Fe3O4-DPD MNPs could serve as an important diagnostic tool for
biomedical imaging.
1. Introduction
Iron oxide magnetic nanoparticles (IONPs) have been sub-
jected to a variety of biomedical applications due to their
remarkable nanoscale physicochemical properties. eir
small size, high surface to volume ratio and size-dependent
[1] magnetic properties make them ideal candidates for
clinical applications, including magnetic resonance imaging
(MRI), in which they serve as T2-contrast enhancement
agents [2–4], hyperthermia treatment of cancer [5–7], cell
separation [8], tissue repair [9], and magnetic force guided
drug delivery [10]. Magnetite (Fe3O4) and its oxidized form
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maghemite (Fe2O3) are the most common IONPs, which
compose the core in a typical core-shell nanoparticle struc-
ture. Among the unique magnetic properties that IONPs
demonstrate upon reducing their magnetic core size above
a critical diameter (less than 20 nm for spherical IONPs),
superparamagnetism is worth noting. IONPs lose their mag-
netization aer the removal of themagnetic eld and thus can
be controllable. Additionally, their surface can be modied
with biocompatible coatings via various methods [11, 12],
rendering them biocompatible and applicable for biological
systems. anks to the ease of surface functionalization,
IONPs are provided with colloidal stability via steric and
electrostatic interactions and high loading capacity via func-
tional (i.e., hydroxyl, carboxyl, amino, and thiol) groups, in
order to be boundwithmany active targetingmolecules (such
as antibodies, aptamers, and peptides) [13–16], drugs, and
detection elements (i.e., radionuclides formolecular imaging,
uorescent molecules) according to demand in biomedical
applications.
Colloidal stability of IONPs is of great importance to be
considered in order to develop an eective imaging agent
able to circulate in the bloodstream for as long as it takes
to be accumulated in the target-organ. However, uncoated
nanoparticles are prone to opsonization and tend to agglom-
erate in vivo (i.e., via Van der Waals, magnetic dipole-dipole,
and hydrophobic interactions), leading to the formation of
micrometer-sized particles, which mostly accumulate in the
organs of the Reticuloendothelial System (RES), resulting
in rapid sequestration from blood circulation. On the other
hand, surface coating with appropriate organic and inorganic
[17, 18] coatings provides IONPs with stealth properties,
increased stability, and reduced cytotoxicity, consequently
improving their potential use for in vivo applications [19].
e need for early cancer diagnosis has led scientists to
a tremendous eort of developing noninvasive multimodal
imaging agents able to detect abnormalities in vivo more
accurately. As a consequence, the necessity of synthesizing
dual-modality imaging agents, such as radiolabeled IONPs,
has emerged in the last years in biomedical sciences, due to
their ability to circumvent the limitations of a single imaging
modality. In fact, conventional imaging modalities, namely,
X-ray computed tomography (CT), optical imaging (OI),
and magnetic resonance imaging (MRI), as well as positron
emission (PET) and single-photon emission (SPECT) tomog-
raphy, widely used in nuclear medicine, possess their own
advantages and disadvantages. Particularly, PET (and/or
SPECT) provides qualitative images with high sensitivity
and specicity; however the anatomical information via this
modality is diminished. On the contrary, MRI provides
necessary anatomical information due to its high spatial
resolution and contrast in so tissue, but it exhibits relatively
poor sensitivity [20]. is is the case why radiolabeled
IONPs surpass conventional imaging modalities, since the
combination of these two modalities (PET/MRI and/or
SPECT/MRI) in a dual-modality agent has a synergistic
result, ultimately exhibiting a much improved potential for
biomedical imaging. Several papers have been reported
concerning radiolabeled IONPs developed for PET/SPECT-
MRI imaging combined with other biomedical applications
like controlled drug delivery and hyperthermia treatment to
achieve both diagnosis and therapy of cancer [21–24].
PET radionuclides such as Fluorine-18 and Carbon-11,
commonly used in clinical practice, require time consuming
and expensive facilities (i.e., on-site cyclotron) to be pro-
duced. On the other hand, radionuclides obtained from a
generator-based system have received signicant attention
since they are inexpensive and easily available at any time
for clinical use. Among them, Gallium-68 (68Ga: T1/2 =
68min) is an attractive radioisotope for PET imaging due
to its high proportion of positron decay (89%) of 1,9Mev
(maximum energy) and its availability from a 68Ge/68Ga
generator permitting three elutions per day. Specically, the
long-lived radionuclide 68Ge (푇1/2 = 270.8 days) decays via
electron capture, providing the 68Ga radionuclide. It is worthy
to be mentioned that few papers have been reported in the
literature, concerning radiolabeling with 68Ga radionuclide
of IONPs, synthesized in various sizes and shapes, to create
dual-modality conjugates able to detect malignancies [25–
28].
e imaging agent described in this work consists of
Fe3O4 MNPs, surface functionalized with the water sol-
uble stabilizer 2,3-dicarboxypropane-1,1-diphosphonic acid
(DPD) and radiolabeled directly with 68Ga for PET imaging.
e substance DPD was used because it is water soluble
and biocompatible, providing the appropriate dispersing
stability and minimizing the potential cytotoxicity of the
naked Fe3O4 MNPs. Furthermore, as a tetradentate ligand
(with two phosphonates and two carboxylate groups), DPD
serves as an eective chelating agent, as has been shown for
90Y, leading to the formation of a highly stable conjugate
[29]. In vitro stability studies were performed with 68Ga-
Fe3O4-DPD MNPs, to assess the stability of the complex
in biological media, while in vitro cytotoxicity studies of
the Fe3O4-DPD MNPs were performed to evaluate their
potential toxicity in both normal and cancer cell lines. To
assess the in vivo behavior of the 68Ga-Fe3O4-DPD MNPs
ex vivo biodistribution studies and dynamic and cumulative
imaging studies were performed in normal animal models.
2. Materials and Methods
2.1. Chemicals. 2,3-Dicarboxypropane-1,1-diphosphonic acid
(DPD) was synthesized at the Laboratory for Radioisotopes
of the “Vincˇa” Institute of Nuclear Sciences, according to a
previously reported procedure [30]. All other reagents and
solvents used in these studies were obtained from com-
mercial sources without further purication. Iron(II) sulfate
hepta-hydrate (FeSO4 × 7H2O), iron(III) sulfate hydrate
(Fe2(SO4)3 ×H2O), sodium hydroxide (NaOH), and aqueous
ammonia solution (25%) were obtained from Sigma-Aldrich.
Puried deionized water was prepared by the Milli-Q system
(Millipore Co., Billerica, MA, USA). A lower activity com-
mercial 68Ge/68Ga generator was acquired from ITG Garch-
ing (Garching, Germany). 30%HCl Suprapur (Merck, Darm-
stadt, Germany), acetone (Sigma-Aldrich), 2,4-pentanedione
99% (Alfa Aesar, Karlsruhe, Germany), and 37% HCl
(Riedel-de Hae¨n) were commercially available and used as
Contrast Media & Molecular Imaging 3
received. Human serum was acquired from Sigma-Aldrich
(St. Louis, MO, USA). e MTT tetrazolium salt, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, was
acquired from ermo Fisher Scientic (Cat. number
M6494).
2.2. Equipment. Radioactivity of the 68GaCl3 eluent was
measured using a dose calibrator (Capintec, Ramsey, NJ).
in layer chromatography (TLC) silica gel 60 sheets (5
× 10 cm) were purchased from Merck (Dermstadt, Ger-
many) and along with a Radio-TLC Scanner (Scan-Ram,
LabLogic, Sheeld, UK) were used in the determination
of radiolabeling yield/purity and in vitro stability studies.
PD-10 columns (GE Healthcare), containing Sephadex G-25
resin, were used for the purication of radiolabeled samples.
Water was deionized to 18MΩ⋅cm using an easy-pure water
ltration system (Barnstead International, Dubuque, Iowa).
Gamma scintillation counter, Cobra II, Canberra, Packard,
was used tomeasure the radioactivity of each organ andblood
samples in ex vivo biodistribution studies. AXIOS-150/EX
(Triton Hellas) dynamic light scattering (DLS) apparatus
equipped with a 30mW He-Ne laser emitting at 658 nm
and an Avalanche photodiode detector at an angle of 90∘
was used for the determination of the size distributions of
the particles. Atomic force microscopy (AFM) images were
obtained by means of a scanning probe microscope [NT-
MDT Solver PRO]. Magnetic measurements of liquid sam-
ples were performed by means of a SQUID magnetometer
(5.5 T MPMS, Quantum Design). An ultrafast absorbance
spectrophotometer (SPECTROstarNano, BMG LABTECH)
for microplates and cuvettes was used in the MTT viability
assay.
e imaging studies were performed on a custom-made
trimodal system, incorporating a PET, a SPECT, and an X-
ray subsystem [31]. For the current study the combination of
PET coincidence imaging andX-rayswas used.edual head
PET system is based on a pair of Position Sensitive Photo-
Multiplier Tubes (PSPMTs), coupled to a 5 × 10 cm2 bismuth
germanium oxide (BGO) scintillator array, with a pixel size
of 2 × 2 × 5mm3 and readout based on programmable ADCs
and FPGA. e two heads are placed at an 80mm distance
and predened acquisition parameters are a timing window
of 16 ns and an energy window between 350 and 700 keV.
e system average spatial resolution in coincidence mode is
3.5mm, the peak sensitivity is 13483 cps/MBq, and the energy
resolution is 30%.e X-ray system consists of an X-ray tube
and a CMOS detector, separated by a distance of 30 cm. e
minimum pixel size is equal to 0.1mm and the active area is
approximately 12 × 12 cm2.
2.3. Synthesis of Fe3O4-DPD MNPs. Magnetite nanoparticles
were prepared by the alkali-mediated chemical coprecipita-
tion of Fe2+ and Fe3+ ions (1 : 2 ratio), as described elsewhere
[32]. In a typical experiment, ferrous sulfate heptahydrate
(0.1M) and ferric sulfate hydrate (0.2M) were dissolved in
deionized water. Subsequently 25% ammonia solution (ca.
20ml) was injected into the ask and stirring was continued
for 1 h at 50∘C to allow the growth of the nanoparticles. e
solution was subjected to magnetic decantation followed by
repeated washing with distilled water. Aer the magnetite
synthesis, the coating reactionwas carried out by the addition
of 0.25 g/2mL DPD water solution (Fe3O4 : DPD = 1 : 1). e
pH of the resultant mixture was adjusted to 8-9 by addition
of 6M NaOH. en, the mixture was stirred overnight at
room temperature and further subjected to dialysis against
deionized water (MWCO 12 kDa) for 1 d to remove the excess
of unreacted DPD.
2.4. Physicochemical Characterization of MNPs. e phase
analysis of the synthesizedMNPs powderwas performed on a
Philips PW1710 X-ray diractometer.e data were collected
in the angular range 10–50∘ (2휃) with a step size of 0.06∘ and a
counting time of 50 s per step. High resolution transmission
electronmicroscopy (HRTEM)was employed to characterize
the morphology, size and size distribution of the MNPs. e
samples of MNPs were prepared by placing one drop of
a dilute suspension of MNPs in water on a carbon-coated
copper grid and allowing the solvent to evaporate at room
temperature. e surface charge of the MNPs was investi-
gated through zeta potential measurements (Zetasizer Nano,
Malvern instruments, UK) at pH between 1 and 11. Fourier
transform-infrared (FTIR) measurements were carried out at
room temperature on a Nicolet 380 spectrometer (ermo
Fischer Scientic, USA) in the spectral range 4000–400 cm−1,
with 4 cm−1 resolution. ermogravimetric analysis (TGA)
was carried out with a SDT Q600 TGA/DSC instrument
(TA Instruments) up to 850∘C, by heating the sample under
a nitrogen ow at a heating rate of 10∘C/min. e residual
weight accounts for the mass of iron oxide nanoparticles in
the ferrouid. Magnetic measurements of powder samples
were performed on a SQUID magnetometer. Magnetization
versus temperature,푀(푇), was measured in 2–300K temper-
ature range, under zero-eld-cooled (ZFC) and eld-cooled
(FC) regimes, in 20Oe. Hysteresis loops were measured at
300K in ZFC regime.
2.5. In Vitro Cytotoxicity Study of Fe3O4-DPD MNPs. Two
epithelial cell lineswere used for the evaluation of cytotoxicity
of Fe3O4-DPD MNPs, namely, HEK293T and 4T1. e
normal cell line HEK293T is a highly transfectable derivative
of human embryonic kidney 293 cell line that stably expresses
the SV40 large T antigen. e 4T1 cell line is a highly
breast metastatic tumorigenic 6-thioguanine resistant cell
line derived from mouse that can metastasize to the lung,
liver, lymph nodes, and brain, while the primary tumor
is growing in situ. HEK293 are used as the control group
(noncancerous cell line) in our experiments. Both cell lines
were acquired from ATCC.
4T1 (ATCC CRL2539) and HEK293T (ATCC CRL-
3216) cell lineswere cultured inDMEMHighGlucoseCulture
Medium (BioSera) containing 10% FBS, 2mmol/L glutamine,
100U/mL penicillin, and 0.1mg/mL streptomycin at 37∘C.
emedium was changed every 48 h and cells were passaged
once weekly using standard trypsin-EDTA concentrations.
Beginning at passage 32 and 37, respectively, cells were
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cultured continuously. Cells were frozen in freezing medium
containing 10% FBS and 5% DMSO.
2.6. MTT Assay. e MTT tetrazolium salt is reduced by
metabolically active cells, via the action of dehydrogenase
enzymes.is leads to the generation of reducing equivalents
such as nicotinamide adenine dinucleotide (NADH) and
nicotinamide adenine dinucleotide phosphate (NADPH).
e resulting intracellular purple formazan, from the initial
yellow color of MTT, can be solubilized and quantied by
spectrophotometry. e MTT cell viability assay measures
alterations in cell viability thus; when metabolic events lead
to apoptosis or necrosis, cell viability is decreased. As a
general protocol, 5000 cells/well were seeded in 96-well plates
(Corning-Costar, Corning, NY) and cultured overnight.
ree dierent types of controls, namely, positive, negative,
and background, were used throughout the study. Positive
control had cells with culture medium but were not exposed
to MNPs. Negative control had MNPs without cells. Back-
ground control had culture medium without cells. e two
dierent cell lines were treated with various concentrations of
MNPs for 24 h. Subsequently, the cells were rinsed once and
incubated at 37∘Cwith 100 휇l serum-freemedium, containing
0.5mg/mL MTT. Aer 1.5 to 2.5 h, 100 휇l of SDS-HCl was
added to each well, mixed with the pipette and incubated
for at least 1 h at 37∘C. e optical densities were read at
570 nm (reference lter was set at 690 nm), using amicroplate
spectrophotometer (SPECTROstarNano, BMG LABTECH).
Absorbances were normalized with respect to the untreated
control cultures to calculate changes in cell viability.
2.7. Labeling of Fe3O4-DPD MNPs with
68Ga. For the radi-
olabeling experiment, 68Ga was eluted from the 68Ge/68Ga
generator [33]. A fraction containing 68GaCl3 (∼45MBq)
in a volume of 100 휇L was used. Radiolabeling was per-
formed by mixing 50휇L of Fe3O4-DPD NPs suspension (C
= 3.2mg/mL dispersed in water), 350 휇L of sodium acetate
buer (0.2M, pH 4), and 100 휇L of 68GaCl3 and incubating
at 90∘C for 40min. e radiolabeling yield was determined
by thin layer chromatography analysis (TLC). e strip was
developed using a 2 : 1 mixture of HCl/Acetone/deionized
water and 2,4-Pentanedione as the mobile phase. With this
system, 68Ga-Fe3O4-DPDMNPs remained at the application
point, while unbound 68Ga3+ ions migrate with the solvent
front.e radiolabeled sample was puried by centrifugation
(12000 rpm, 10min). Aer washing twice with deionized
water, the supernatant was removed and the radiolabeled
sample was redispersed in deionized water. e % radio-
chemical purity of 68Ga-Fe3O4-DPD MNPs was determined
by TLC, as previously described. A control test was also
carried out, in the absence of Fe3O4-DPDMNPs.
2.8. In Vitro Stability Studies of 68Ga-Fe3O4-DPD MNPs. To
evaluate the in vitro stability of 68Ga-Fe3O4-DPD MNPs, a
sample of 10 휇L 68Ga-Fe3O4-DPDMNPs was incubated with
90 휇L phosphate buer saline (PBS) pH 7.4 while shaking at
room temperature. For serum stability studies, 20휇L 68Ga-
Fe3O4-DPDMNPswere incubatedwith 180휇L human serum
at 37∘C. e in vitro stability was determined at three time
points (30, 60, and 120min) by TLC, as described above.
2.9. Determination of the Size of 68Ga-Fe3O4-DPD MNPs.
Atomic force microscopy (AFM) was used to assess the
morphology and the size of 68Ga-Fe3O4-DPD MNPs. All
measurements concerning the 68Ga-labeled MNPs were per-
formed aer the decay of 68Ga to the nonradioactive isotope
68Zn, in order to avoid any contamination due to the radioac-
tive sample. Initially, the samples were spread onto cleaned
standard microscope slides by means of an electronically
rotating platform (rotation frequency 2000 rpm, rotation
duration 10 sec) to prepare single layer lms. en, AFM
images of the lms were obtained by means of a scanning
probe microscope [NT-MDT Solver PRO] set in noncontact
tapping mode.
Dynamic light scattering (DLS) was also used to mea-
sure the size distributions of Fe3O4-DPD MNPs and68Ga(→68Zn)-Fe3O4-DPDMNPs in aqueous solutions using
a DLS apparatus. In a typical DLS measurement, 60휇L
of Fe3O4-DPD MNPs or 100휇L of 68Ga(→68Zn)-Fe3O4-
DPD MNPs diluted with 300 휇L ultrapure water was mea-
sured at 22∘C. For each dispersion, at least ten light scat-
tering measurements were collected and the results were
averaged.
2.10. Magnetic Properties of Fe3O4-DPD and
68Ga-Fe3O4-
DPD MNPs. e magnetic measurements of Fe3O4-DPD
and 68Ga-Fe3O4-DPD samples were performed bymeans of a
SQUID magnetometer (5.5 T MPMS, Quantum Design). As
mentioned above, these measurements were performed aer
the decay of 68Ga to the stable isotope 68Zn. Each sample
was measured at body temperature, 푇 = 36∘C, and in liquid
form, dispersed in bidistilled water. To this end, we employed
a plastic cylindrical container of appropriate diameter (∼
5mm) that ts the opening of the SQUID sample chamber.
e container was lled with 190휇l MNPs (0.608mg, C
= 3.2mg/ml) and sealed carefully. Magnetization measure-
ments versus magnetic eld,푀(퐻), were performed both on
the empty container and the sample-lled container under
the exact same conditions. us, we were able to isolate
the푀(퐻) data of the Fe3O4-DPD and 68Ga(→68Zn)-Fe3O4-
DPD MNPs samples by subtracting the signal of the empty
container.
2.11. Ex Vivo Biodistribution Studies. Animal experiments
were carried out according to European and national reg-
ulations. ese studies have been further approved by the
Ethics Committee of the NCSR “Demokritos” and animal
care and procedures followed are in accordance with insti-
tutional guidelines and licenses issued by the Department of
Agriculture and Veterinary Policies of the Prefecture of Attiki
(Registration numbers: EL 25 BIO 022 and EL 25 BIO 021).
Normal Swiss mice were obtained from the breeding facili-
ties of the Institute of Biosciences and Applications, NCSR
“Demokritos.” e animals were housed in air-conditioned
rooms under a 12 h light/dark cycle and allowed free access to
food and water.
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e sample of 68Ga-Fe3O4-DPD MNPs was loaded onto
a size exclusion PD-10 column, containing Sephadex G-25
resin and eluted with phosphate buer saline (PBS), in order
to eliminate aggregated 68Ga-Fe3O4-DPDMNPs, which may
cause venous thrombosis during tail injections of the sample
in the animals. Ten 0.5ml fractions were collected, and the
radioactivity of each fraction was measured using a dose
calibrator (Capintec). e fractions containing the highest
radioactivity were pooled and used for the study.
e in vivo behavior of 68Ga-Fe3O4-DPDMNPswas eval-
uated in 9 normal Swiss mice (weight 23–27 gr). Intravenous
administration of 100 휇l PBS suspension (11.11 휇g/100 휇l 68Ga-
Fe3O4-DPD MNPs per mouse) of puried
68Ga-Fe3O4-
DPD MNPs was performed via the tail vein. e animals
were sacriced at 30, 60, and 120min postinjection (3 mice
per time-point). en, samples of blood and organs were
excised, weighed, andmeasured for radioactivity in aGamma
scintillation counter. e remaining radioactivity in the
tail, as well as background counts was subtracted, and the
radioactivity decay was autocorrected by the counter. en,
the accumulation of 68Ga-Fe3O4-DPD MNPs in each organ
was expressed as the percentage injected activity per gram of
tissue (% IA/g± SD) and calculated compared to the activities
of a standard dose of the injected solution.
2.12. In Vivo Imaging Studies. Dynamic coincidence images
of the administered mice were obtained from 10min up to
60min p.i. Successive 2min frames were collected, showing
the gradual biodistribution of the studied substance. Frames
were also summed, to achieve cumulative images of higher
statistics. All functional images were planar, coincidence
images and no tomographic reconstruction was performed.
Upon completion of the coincidence imaging, X-ray images
were also acquired at the exact same mouse positioning to
act as an anatomical guide for the organs’ exact location.
e X-ray imaging parameters were set to 35 kVp, 500휇A,
and 0.1 s exposure time. Fusion between coincidence and X-
ray images was performed semiautomatically through an in-
house standard procedure. e two heads were not rotated
and no tomographic imaging was performed.
e images were stored in raw format and postprocessed
with ImageJ open source soware (version 1.49v; NIH).en,
they were linearly interpolated, to provide a smoother nal
image. No smoothing algorithm was used. ImageJ was also
used to select the color map and enhance image contrast at
a certain level where the organs/structures of interest can be
distinguished.
3. Results and Discussion
In the present study, Fe3O4 nanoparticles have been coated
with DPD.e primary idea behind the design and synthesis
of these MNPs was to improve stability and biocompatibility,
as well as provide a platform for the development of a
theranostic agent. As was recently shown in a study by Djokic´
et al. [29], MNPs coated with DPD eciently complexed
Yttrium-90, leading to a radiolabeled species for therapeu-
tic applications. Furthermore, DPD oers the capability to
Phosphonate group
Carboxyl group
Figure 1: DPD ligand.
radiolabel the same MNPs with 68Ga, for diagnostic applica-
tions.
3.1. Synthesis and Characterization of the Fe3O4-DPD MNPs.
In this study, MNPs were synthesized according to the
coprecipitation method and stabilized with the tetradentate
ligand DPD (Figure 1). e surface of MNPs was modied
with hydrophilic carboxylate andphosphonate groups shortly
aer the particle formation, resulting in increased stability
and dispersibility of the carrier in aqueous solution.
Transmission electron microscopy (TEM) was used in
order to determine particle size and the distribution and
morphology of Fe3O4-DPD MNPs (Figure 2(a), (A) and
(B)). From TEM micrographs, it is observed that the MNPs
were pseudospherical or discrete squares with a diameter of
around 6 nm. Particles were agglomerated due to magnetic
interactions among them.
Crystal structures of the MNPs were checked by X-
ray powder diraction method. In the obtained diraction
patterns (Figure 2(b)) all reections were indexed in the
expected space group, Fd3m, and spinel structure type. e
mean crystallite diameter of 5.6 nm was estimated for the
Fe3O4 using Scherer’s equation and the peak half-height
width of the (311) reections. e same values were obtained
using XRD data for pure Fe3O4 and Fe3O4-DPD MNPs.
e mean crystallite size calculated from the XRD patterns
is consistent with particle size estimated from the relevant
TEM micrographs. Hence, particles are composed from one
crystallite.
DLS measurements were carried out on the Fe3O4-DPD
MNPs (Figure 3(a)). e sample was diluted with ultrapure
water and measured at 22∘C. A sharp monomodal size distri-
bution of theMNPswas observed.UsingCONTINanalysis of
DLS measurements, it was found that the mean size distribu-
tion of intensity weighted hydrodynamic diameter of Fe3O4-
DPD MNPs was 96 nm. e polydispersity index (PDI)
of Fe3O4-DPD MNPs was calculated from the cumulants
analysis and its value was less than 0.3, indicating that the
nanoparticles have a considerably narrow size distribution
and are essentially monodispersive. As PDI values are very
sensitive to the presence of aggregates, it is obvious that the
Fe3O4-DPD MNPs are stable since PDI is not aected over
time (Table 1). It should be noticed that the results obtained
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Figure 2: ((a), (A) and (B)) TEM images of DPD-coated MNPs; (b) XRD patterns of Fe3O4 and Fe3O4-DPDMNPs.
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Figure 3: (a) Intensity weighted hydrodynamic radii size distribution of Fe3O4-DPD MNPs; (b) dependence of zeta potential of Fe3O4 and
Fe3O4-DPDMNPs on the change of pH.
from DLS and TEM are dierent since the rst obtained
direct from solution andmeasured the hydrodynamic radii of
the particles, while the second obtained from dried solution
where the particles aggregated due to the removal of water.
Zeta potential measurements as a function of pH for the
Fe3O4 and Fe3O4-DPD MNPs are shown in (Figure 3(b)).
Due to the presence of carboxylate and phosphonate groups
on the surface of Fe3O4-DPD MNPs, the surface charge of
the MNPs was observed to be highly negative (−50.4mV at
pH = 7) and shows high electrostatic repulsions between the
charged nanoparticles, which ensures the colloidal stability.
Again, this conrms the eciency of coating since the
IEP (1.9) has been shied to lower pH values compared
to naked MNPs (6.2). e correlation of zeta potential to
pH is important to know so that one can predict how the
pH inside the human body will aect the surface charge
of the nanoparticles and therefore protein adsorption onto
nanoparticles. Fe3O4-DPD MNPs showed high stability in
Table 1: Stability analysis of Fe3O4-DPD MNPs, variation in PDI
and zeta potential against time.
Time (months) 1 2 3 4 5 6
PDI 0.255 0.241 0.267 0.287 0.263 0.271
Zeta potential (mV) −49.8 −50.1 −48.6 −49.2 −50.3 −50.4
aqueous medium as their size and zeta potential remained
unaected over a long period of time (Table 1).
Further conformation of eective coating of the DPD
ligand on the surface of MNPs came from FTIR spectroscopy
and thermogravimetric analysis. e infrared spectra of the
free ligand DPD, Fe3O4 MNPs, and Fe3O4-DPD MNPs are
shown for comparison (Figure 4(a)). DPD could coordinate
the metal through the carboxylate and the phosphonate
groups. In that case signicant changes for the bands of
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Figure 4: (a) ATR-FTIR spectra of DPD, Fe3O4, and Fe3O4-DPDMNPs; (b) TGA curves of Fe3O4 and Fe3O4-DPDMNPs.
the carboxylate and the phosphonate groups of the Fe3O4-
DPD complex should be seen in its infrared spectra. e
most important dierences between DPD and Fe3O4-DPD
spectra are related to the phosphonate bands in the region
1200–800 cm−1.
Comparing the Fe3O4-DPD MNPs (red curve) with the
freeDPD ligand (green curve) (Figure 4(a)), the large changes
observed within the P–O stretching region (1200–900 cm−1)
show that a strong interaction between the phosphonate
group and the Fe3O4 is present.e spectrumof the freeDPD
exhibits, within the P–O stretching region (1200–900 cm−1),
two sharp peaks at 1204 and 918 cm−1, assigned to P=O
and P–OH, respectively. e broadband at 1040 cm−1 in
the spectrum of Fe3O4-DPD MNPs is characteristic for the
vibrational mode for the PO3
2− group. Appearance of this
broad phosphoryl band, as well as the disappearance of
the P=O and P–O–H bands, indicates a mainly tridentate
binding of DPD to the surface of Fe3O4 MNPs. For the DPD
ligand, the carboxylate ions present two characteristic bands
at 1704 and 1414 cm−1 due to the asymmetric and symmetric
carboxylate stretches, respectively. Comparing the Fe3O4-
DPDMNPs with the free DPD, the characteristic carboxylate
stretches were shied to lower frequencies at 1635 and
1396 cm−1, respectively, which suggests that DPD molecules
are bound to the particle surface also via –COO− groups.e
ATR-FTIR spectrumof Fe3O4-DPDMNPs exhibited a strong
band at 540 cm−1, characteristic of the Fe-O vibration related
to the magnetite core. ermogravimetric analysis (TGA)
of naked MNPs detected no signicant peaks (Figure 4(b)).
ere was a 3%weight loss as the temperature increased from
100∘C to 800∘C, which might be due to a loss of absorbed
water. In contrast, the functionalized MNPs lost weight in
two steps. e rst step occurred over the range 25–200∘C
and might also be due to the loss of absorbed water. e
second step consisted of a weight loss of about 12.5% over
the range 200–450∘C and might be due to the burning of
bonded ionic liquids. At higher temperatures of 450–900∘C,
the weight remained constant, implying the presence of only
Fe3O4 le within the temperature range.
Magnetic properties of Fe3O4 and Fe3O4-DPD MNPs
were investigated by magnetization measurements versus
eld, 푀(퐻) at 290K as well as by ZFC-FC magnetization
from 2–300K in applied eld of 100Oe.Magnetization versus
eld, 푀(퐻), curves are shown in Figure 5(a). It can be
observed that the magnetization does not fully saturate up to
50 kOe, reecting the hard magnetic behavior of the particle
surface. e saturation magnetization, Ms, as determined
by extrapolating 푀(1/퐻) to H = 0, was Ms = 47 and
42 emu/g, for Fe3O4 and Fe3O4-DPD, respectively. Remanent
magnetization,푀푅, and coercivity,퐻퐶, values are nearly zero,
in agreement with the superparamagnetic behavior expected
for these nanoparticles on the time scale of magnetization
measurement time 휏M ∼ 100 s. Temperature dependencies of
ZFC and FCmagnetization for Fe3O4 and Fe3O4-DPDMNPs
are shown in Figure 5(b). e ZFC and FC magnetization
curves furcate at the maximum temperature of measure-
ments, 300K. A broad maximum in ZFC branch around
200K is a consequence of a broad particle size distribution,
as was shown by TEM examinations (Figure 2(a), (B)). In the
FC branches magnetization increases a little bit from room
temperature to 100K, and below it shows a tendency to be
saturated. e found FC behavior indicates the interparticle
interactions and probably a spins glass state.
3.2. In Vitro Cytotoxicity Study of Fe3O4-DPD MNPs.
Although the chemical characterization of the synthesized
Fe3O4-DPD MNPs is crucial in order to further characterize
their diagnostic utility as a PET radiotracer, quantitative
assays of the metabolic activity of cancer cell lines could
grant a better knowledge of the mechanisms implied in
the toxicity caused by those MNPs. e assays based on
the measurement of the metabolic activity of the cells are
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Figure 6: MTT cell viability assay aer 24 h treatment of (a) 4T1 cells and (b) HEK293T cells with Fe3O4-DPDMNPs. Positive control shows
cells without exposure to MNPs. Cell viability is expressed as % cell viability ± SD between two experiments.e symbols ∗∗ and ∗∗∗ show
statistical signicance using one-way ANOVA (푝 < 0.01 and 푝 < 0.005, resp.), compared to positive control.
the most common methods in order to designate the cell
viability under nanoparticle treatment. e MTT viability
assay intends to track the activity of reductase enzymes in
order to measure the cell viability of 4T1 and HEK293 cell
lines and thus the cytotoxicity caused by treatment with
various concentrations of Fe3O4-DPDMNPs (3, 5, 10, 20, 25,
and 30 휇g/ml) for 24 h, an appropriate incubation time for
Fe3O4-DPDMNPs internalization from the cells [34].
According to our results, the viability of cancer 4T1 cells
shows a 50% reduction (푝 < 0.005) when treated with
20휇g/ml, while the viability of the cells falls to 20% under
treatment with 30 휇g/ml (푝 < 0.005) of Fe3O4-DPD MNPs
(Figure 6(a)). us, the cytotoxicity results demonstrate a
dose-dependent cytotoxicity eect of Fe3O4-DPD MNPs in
4T1 cancer cell line. Recently, several in vitro experiments
in eukaryotic cells show that internalized MNPs, depending
on their size and modication, can induce mitochondrial
dysfunction, increase the level of ROS, and subsequently
cause DNA damage, chromosomal aberrations, apoptosis,
impairment of the cell membrane, and cell cycle rest. e
later eects are probably caused by the ions released (ROS
generation) by magnetic MNPs that lead to the ignition of
oxidative stress responses into the cell and at the end to
cytotoxicity. Moreover, although iron MNPs degraded in the
cell, they can change the cellular iron pool, leading to aberrant
expression of transferrin receptor, cyclins, and induction
of apoptotic responses [35–37]. Regarding cytotoxicity, the
choice of the cell line tested under MNPs treatment is
of great importance, since it is demonstrated that MNPs
toxicity is highly cell-type dependent [38, 39]. erefore, the
cytotoxicity of Fe3O4-DPD MNPs against a noncancerous
cell line (HEK293) was also tested and it was shown that
toxicity against this cell line is greatly reduced, compared to
the 4T1 cell line (Figure 6(b)). Even at a concentration of
30 휇g/ml the viability is >60% (푝 < 0.005). ese results
indicate selective cytotoxic eects of Fe3O4-DPD MNPs in
cancer cells with regard to normal cells. Further experiments
are needed in order to elucidate the mechanism by which
Fe3O4-DPD MNPs cause higher cytotoxicity in cancer cells,
thus highlighting their potential use as therapeutic agents.
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3.3. Radiolabeling of Fe3O4-DPD MNPs with
68Ga. Fe3O4-
DPD MNPs were radiolabeled with 68Ga radionuclide with-
out the presence of a chelator. In our study DPD, a tetraden-
tate ligand with two phosphonates and two carboxylates
serves as an eective ligand that coordinates with 68Ga3+.
e radiolabeling yield of the sample was found to be ∼
70%, as determined by radio-TLC analysis. Moreover, the
radiolabeled sample was puried via centrifugation and
aorded a radiochemical purity of >91%. e radiolabeling
results are in agreement with the literature [21, 40–44].
3.4. In Vitro Stability Studies of 68Ga-Fe3O4-DPD MNPs.
A signicant factor to be considered when developing a
new radiolabeled nanoparticle is that the radionuclide must
be bound to the nanoparticle to form a stable conjugate
under physiological conditions to avoid their separation and
nonspecic deposition of free ions in tissues. Otherwise,
biodistribution and imaging data will not indicate the fate of
nanoparticles, as the radionuclide distribution will not reect
that of the nanoparticles.
With the aim of assessing the in vitro stability of 68Ga-
Fe3O4-DPD MNPs in biological media, the radiolabeled
sample was incubated with PBS and human serum. e
results exhibited satisfactory in vitro stability in PBS (∼80%
stable 68Ga-Fe3O4-DPD MNPs) and high in vitro stability
in human serum (>92% stable 68Ga-Fe3O4-DPD MNPs), as
evaluated by TLC analysis, at three time points (30, 60, and
120min) aer incubation. Our results are in accordance with
work reported by other groups [18, 21, 26, 28, 40, 41].
3.5. Determination of theMorphology and Size of 68Ga-Fe3O4-
DPD MNPs. e size of radiolabeled magnetic nanopar-
ticles highly aects their pharmacokinetics and in vivo
behavior. Nanoparticles larger than 200 nm are sequestered
by macrophages of liver and spleen, while nanoparticles
smaller than 10 nm are rapidly removed through renal clear-
ance. Also, nanoparticles bigger than 4 휇m in diameter are
mainly captured in the lungs and may lead to the risk
of embolism. us, nanoparticles with a mean size in the
range of 10–200 nm escape opsonization exhibit longer blood
circulation times and are most eective for biological appli-
cations. In our study, AFMmeasurements were performed to
assess the size of the 68Ga-Fe3O4-DPD MNPs as described
elsewhere [45]. ese measurements were performed aer
the decay of 68Ga to the stable isotope 68Zn, as mentioned
in Materials and Methods.
e acquired AFM images showed that the size of
68Ga(→68Zn)-Fe3O4-DPD MNPs ranged from 30 to 180 nm
(푁 = 87 nanoparticles measured from several AFM images).
As shown in Figure 7(a) the nanoparticles are homogenous
and spherical, while the majority of the nanoparticles are
less than 50 nm (Figure 7(b)). Some aggregates of varying
sizes may be created in the radiolabeled sample during the
radiolabeling process. It has also been reported that PEG-
coated superparamagnetic iron oxide nanoparticles subjected
to high salt concentration (0.2M ammonium acetate buer)
during radiolabeling procedure with 68Ga exhibit larger size
compared to their size before the radiolabeling [27].
DLS measurements were also carried out on the radi-
olabeled sample following the procedure described above.
Also in this case, a sharp monomodal size distribution
of 68Ga(→68Zn)-Fe3O4-DPD MNPs with average intensity
weighted hydrodynamic diameters of about 400–500 nm
was observed (Figure 8). e value of mean diameter is
higher than that of the nonradiolabeled sample due to the
radiolabeling process as mentioned before.
3.6. Magnetic Properties of Fe3O4-DPD and
68Ga(→68Zn)-
Fe3O4-DPD MNPs. Figure 9 shows representative magne-
tization measurements of Fe3O4-DPD and
68Ga(→68Zn)-
Fe3O4-DPD MNPs as they were measured by means of a
SQUID magnetometer at conditions of body temperature (T
= 36∘C) and in liquid form (dispersed in bidistilled water)
since we wanted to simulate, at least at the laboratory level,
the conditions that these conjugates will ultimately be used
in subsequent studies on animal models. As shown in this
gure, the saturation magnetization of Fe3O4-DPD MNPs
is Ms = 44 emu/g, while that of
68Ga(→68Zn)-Fe3O4-DPD
MNPs is Ms = 8 emu/g. e observed reduction of Ms is
attributed to two unavoidable factors: rst, the reduction of
the eective concentration of the Fe3O4 content during the
radiolabeling process of the Fe3O4-DPDMNPs sample (mass
loss of Fe3O4 during centrifugation/washing cycles needed
to remove free 68Ga that possibly exists in the supernatant
and inability to completely remove all supernatant before the
nal dilution to the specied nal liquid volume); second, to
the change in the chemical composition of Fe3O4 to Fe2O3
due to oxidization (the radiolabeling process is performed in
atmosphere, at relatively high temperature conditions, T =
90∘C). Finally, we should note that neither the Fe3O4-DPD
nor the 68Ga(→68Zn)-Fe3O4-DPD MNPs were aggregated
even under the application of a magnetic eld as high as
20 kOe.
3.7. Ex Vivo Biodistribution Studies. e ex vivo biodistri-
bution of 68Ga-Fe3O4-DPD MNPs was performed to assess
their in vivo behavior as potential PET/MRI imaging agents.
e 68Ga-Fe3O4-DPD MNPs were administered via tail vein
injection in normal Swiss mice. In general, the accumulation
of 68Ga-Fe3O4-DPD MNPs in the organs at all time points
examined is presented in Figure 10, as percentage of injected
activity per gram tissue (% IA/gr ± SD). 68Ga-Fe3O4-DPD
MNPs were distributed throughout the organs, while in liver
and spleen the uptake was the highest. Specically, the blood
retention of the nanoparticles was 2.19 ± 0.42% IA/g up to
60min postinjection (p.i.) and showed a decrease to 1.49 ±
0.92% IA/g at 120min p.i. e accumulation of 68Ga-Fe3O4-
DPDMNPs in the heart was increasedwith time (1.41±0.42%
IA/g at 30min, 1.87±0.20% IA/g at 60min, and 1.99±0.35%
IA/g at 120min p.i.). On the contrary, in the lungs the uptake
showed opposite behavior (2.10±0.49% IA/g at 30min, 1.57±
0.43% IA/g at 60min, and 1.32 ± 0.69% IA/g at 120min p.i.).
e small percentage of the uptake in lungs can be attributed
to possible embolization caused by postinjection aggregation.
e organs of the reticuloendothelial system (RES)
exhibit the highest accumulation of 68Ga-Fe3O4-DPDMNPs,
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Figure 7: (a) Typical AFM image showing themorphology of 68Ga(→68Zn)-Fe3O4-DPDMNPs; (b) size distribution of 68Ga(→68Zn)-Fe3O4-
DPDMNPs measured from several AFM images.
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Figure 8: Intensity weighted hydrodynamic radii size distribution
of 68Ga(→68Zn)-Fe3O4-DPDMNPs.
compared to the other organs. In the liver, there were 32.42 ±
16.12, 42.52 ± 1.95, and 44.66 ± 22.86% IA/g at 30, 60, and
120min p.i., while in the spleen the uptake reached the 16.48±
3.58% IA/g at 60min p.i. and remained relatively constant
(16.21 ± 1.74% IA/g) up to 120min p.i. ese organs are
rich in macrophages (i.e., liver’s Kuper cells), which are able
to recognize and engulf 68Ga-Fe3O4-DPD MNPs through
phagocytosis.e kidney uptake was relatively low at all time
points. All other organs studied showed low or negligible
uptake.
It is well known that following intravenous injection
of radiolabeled magnetic nanoparticles in the bloodstream,
plasma proteins, namely, opsonins, are adsorbed onto the
surface of the nanoparticles [46]. ese plasma proteins are
recognized by the macrophages mostly found in the liver and
spleen, resulting in rapid clearance of the nanoparticles from
the bloodstream.e opsonization process and therefore the
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Figure 9: Magnetization versus magnetic eld at T = 36∘C for
Fe3O4-DPD and
68Ga(→68Zn)-Fe3O4-DPD MNPs. Both samples
were in liquid form, dispersed in bidistilled water.
in vivo behavior of the radiolabeled magnetic nanoparticles
are highly aected by their physicochemical properties, such
as their coating, size and surface charge.
Despite the coating with DPD, a biocompatible and
hydrophilic coating, the 68Ga-Fe3O4-DPD MNPs displayed
long-term retention in the liver, as discussed above. is
behavior was similar to 90Y-labeled Fe3O4 MNPs coated
with PEG600 diacid, with a size of 46 ± 0.6 nm [18]. is
behavior may be attributed to the size of the 68Ga-Fe3O4-
DPDMNPs as measured with AFM [46, 47]. As discussed by
Contrast Media & Molecular Imaging 11
B
lo
o
d
H
ea
rt
L
iv
er
Sp
le
en
L
u
n
g
K
id
n
ey
St
o
m
ac
h
In
te
st
in
e
P
an
cr
ea
s
M
u
sc
le
B
o
n
e
0
1
2
3
4
5
6
7
8
20
30
40
50
60
70
%
 I
A
/g
30 min
60 min
120 min
Figure 10: Ex vivo biodistribution study of 68Ga-Fe3O4-DPDMNPs
in normal Swiss mice performed at 30, 60, and 120min postinjec-
tion.
Chouly et al. [48], a similar behavior was observed for 59Fe-
labeled dextran-coated Fe3O4 MNPs with dierent diameters
(30 nm–100 nm). When injected in Swiss mice, they showed
decreased blood retentionwith increasing size, while the liver
accumulation was increased following the increasing size of
the nanoparticles.
Another fact to be considered is the surface charge
of Fe3O4-DPD MNPs. It has been shown that a neutral
charge interacts minimally with the plasma proteins and thus
contributes to the extended circulation time of the MNPs,
whereas a high surface charge enhances the phagocytosis pro-
cess [46]. Positively charged nanoparticles show nonspecic
internalization rate, plasma protein binding, aggregation, and
short blood circulation half-life [47]. In a study carried out
using dextran-coated Fe3O4 MNPs with dierent surface
charges (neutral, negative −30mV, positive +20mV) [48], the
accumulation of nanoparticles in the liver was 3 times lower
for the neutral nanoparticles than the charged ones, while
the negatively charged nanoparticles exhibited increased liver
uptake. In our study, the highly negative surface charge
of Fe3O4-DPD MNPs (−50.4mV at pH = 7) led to high
electrostatic repulsions between the charged nanoparticles,
thus ensuring the colloidal stability of the nanoparticles,
while their high liver uptake can be attributed to their
negative surface charge.
3.8. In Vivo Imaging Studies. Dynamic and cumulative
imaging studies of anesthetized healthy Swiss mice were
performed on a dedicated small animal PET/X-ray system,
up to 1 hour p.i. (Figure 11). Imaging and biodistribution
studies were found to be in good agreement. Kidney uptake
is not discernable in the PET images, due to the signicant
concentration in the liver and the partial overlapping of
kidneys with liver and intestines.
Figure 11: Cumulative PET/X-ray images of a normal Swiss mouse
injected with 68Ga-Fe3O4-DPDMNPs at 20, 30, and 60min p.i. e
gradual alteration in color indicates a lower to higher number of
recorded counts.
4. Conclusions
Iron oxide nanoparticles were successfully synthesized and
surface functionalized with the biocompatible and water
soluble stabilizer DPD, providing the bare Fe3O4 MNPs
with the appropriate dispersing stability, minimizing their
potential cytotoxicity and exhibiting chelating properties.
Fe3O4-DPD MNPs showed reduced toxicity in the normal
cells, compared to cancer cells and ecient labeling with the
positron emitter Ga-68 to form stable constructs. Although
ex vivo biodistribution and in vivo PET imaging studies of
68Ga-Fe3O4-DPD MNPs showed high accumulation in the
RES organs, they indicated satisfactory blood retention at
30, 60, and 120min p.i. As a result, 68Ga-Fe3O4-DPD MNPs
exhibit great potential as a PET/MR imaging agent. We are
currently working on the assessment of 68Ga-Fe3O4-DPD
MNPs in tumor bearing animal models to evaluate their
application in cancer imaging.
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